JP2022513729A5 - - Google Patents
Info
- Publication number
- JP2022513729A5 JP2022513729A5 JP2021532041A JP2021532041A JP2022513729A5 JP 2022513729 A5 JP2022513729 A5 JP 2022513729A5 JP 2021532041 A JP2021532041 A JP 2021532041A JP 2021532041 A JP2021532041 A JP 2021532041A JP 2022513729 A5 JP2022513729 A5 JP 2022513729A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- sequence
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024177850A JP2025016505A (ja) | 2018-12-07 | 2024-10-10 | ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776877P | 2018-12-07 | 2018-12-07 | |
| US62/776,877 | 2018-12-07 | ||
| PCT/US2019/065212 WO2020118295A1 (en) | 2018-12-07 | 2019-12-09 | Humanized and affinity-matured anti-ceacam1 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024177850A Division JP2025016505A (ja) | 2018-12-07 | 2024-10-10 | ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513729A JP2022513729A (ja) | 2022-02-09 |
| JP2022513729A5 true JP2022513729A5 (https=) | 2022-12-19 |
Family
ID=70973892
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532041A Withdrawn JP2022513729A (ja) | 2018-12-07 | 2019-12-09 | ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体 |
| JP2024177850A Pending JP2025016505A (ja) | 2018-12-07 | 2024-10-10 | ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024177850A Pending JP2025016505A (ja) | 2018-12-07 | 2024-10-10 | ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12173066B2 (https=) |
| EP (1) | EP3906261A4 (https=) |
| JP (2) | JP2022513729A (https=) |
| CN (2) | CN120209144A (https=) |
| AU (1) | AU2019393077A1 (https=) |
| CA (1) | CA3121580A1 (https=) |
| WO (1) | WO2020118295A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3906261A4 (en) * | 2018-12-07 | 2022-12-21 | The Brigham And Women's Hospital, Inc. | HUMANIZED AND AFFINITY MATURED ANTI-CEACAM1 ANTIBODIES |
| IT202100033002A1 (it) * | 2021-12-29 | 2023-06-29 | Diatheva S R L | Anticorpi umani e loro usi |
| US20250154251A1 (en) * | 2022-02-03 | 2025-05-15 | The Brigham And Women's Hospital, Inc. | Companion diagnostic for human ceacam1 directed therapeutic agents |
| WO2024213096A1 (en) * | 2023-04-13 | 2024-10-17 | Suzhou Neologics Bioscience Co., Ltd. | Ceacam1-targeting antibodies and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180077322A (ko) * | 2009-04-30 | 2018-07-06 | 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드． | 항-ｃｅａｃａｍ1 항체들과 이를 이용하는 방법들 |
| RU2012153241A (ru) * | 2010-05-11 | 2014-06-20 | Авео Фармасьютикалз, Инк. | Антитела к fgfr2 |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| US9556271B2 (en) * | 2011-12-01 | 2017-01-31 | The Brigham And Women's Hospital, Inc. | Anti-CEACAM1 recombinant antibodies for cancer therapy |
| PL3763387T3 (pl) * | 2013-11-25 | 2024-07-29 | Famewave Ltd | Kompozycje zawierające przeciwciała anty-ceacam1 i anty-pd do terapii nowotworu |
| US10550196B2 (en) | 2014-04-27 | 2020-02-04 | Famewave Ltd. | Humanized antibodies against CEACAM1 |
| WO2016120331A1 (de) * | 2015-01-28 | 2016-08-04 | Karl Sebastian Lang | Agonistische anti-cd66cd66 antikörper für die antiviralen therapie |
| US20180153986A1 (en) * | 2015-04-24 | 2018-06-07 | The Brigham And Women's Hospital, Inc. | Interactions between ceacam and tim family members |
| CN110475788A (zh) * | 2017-03-24 | 2019-11-19 | 财团法人牧岩生命科学研究所 | 抗ceacam1抗体及其应用 |
| EP3906261A4 (en) * | 2018-12-07 | 2022-12-21 | The Brigham And Women's Hospital, Inc. | HUMANIZED AND AFFINITY MATURED ANTI-CEACAM1 ANTIBODIES |
-
2019
- 2019-12-09 EP EP19893377.2A patent/EP3906261A4/en active Pending
- 2019-12-09 US US17/311,258 patent/US12173066B2/en active Active
- 2019-12-09 CN CN202510125669.1A patent/CN120209144A/zh active Pending
- 2019-12-09 JP JP2021532041A patent/JP2022513729A/ja not_active Withdrawn
- 2019-12-09 AU AU2019393077A patent/AU2019393077A1/en active Pending
- 2019-12-09 WO PCT/US2019/065212 patent/WO2020118295A1/en not_active Ceased
- 2019-12-09 CN CN201980091531.7A patent/CN113840839B/zh active Active
- 2019-12-09 CA CA3121580A patent/CA3121580A1/en active Pending
-
2024
- 2024-10-10 JP JP2024177850A patent/JP2025016505A/ja active Pending
- 2024-11-19 US US18/952,149 patent/US20250074980A1/en active Pending